

# QUASAR (stands for QUick and Simple And Reliable). UKCCCR randomised study of adjuvant chemotherapy in colon and rectal cancer

<b>Submission date</b> 06/04/2000	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 06/04/2000	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 17/10/2018	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Richard Gray

**Contact details**  
University of Birmingham Clinical Trials Unit  
University of Birmingham  
Park Grange  
1 Somerset Road  
Edgbaston  
Birmingham  
United Kingdom  
B15 2RR  
+44 (0)121 415 9100  
r.gray@bham.ac.uk

## Additional identifiers

**ClinicalTrials.gov (NCT)**  
NCT00005586

**Protocol serial number**

G9436870/G9521239

## Study information

**Scientific Title**

QUASAR (stands for QUick and Simple And Reliable). UKCCCR randomised study of adjuvant chemotherapy in colon and rectal cancer

**Acronym**

QUASAR

**Study objectives**

Reliable assessment, among patients who have undergone apparently curative surgery for colorectal cancer, of the balance of benefits and risks of adjuvant chemotherapy. Patients for whom there is substantial uncertainty whether or not they should receive chemotherapy are randomised between chemotherapy versus open control. Patients considered to have a clear indication for chemotherapy were randomised (until 1997) between different chemotherapy regimens. Of those who receive adjuvant chemotherapy, the four treatment regimens were:

1. 5-FU (370 mg/m<sup>2</sup>) + 175 mg L-folinic acid + levamisole
2. 5-FU (370 mg/m<sup>2</sup>) + 175 mg L-folinic acid + placebo
3. 5-FU (370 mg/m<sup>2</sup>) + 25 mg L-folinic acid + levamisole
4. 5-FU (370 mg/m<sup>2</sup>) + 25 mg L-folinic acid + placebo

given either daily for five days every four weeks for a total of six cycles, or once-weekly for thirty weeks. Since 1997 patients allocated chemotherapy all receive arm four (without placebo).

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Not Specified

**Health condition(s) or problem(s) studied**

Colorectal Cancer

**Interventions**

Chemotherapy versus open control

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Chemotherapy: Fluorouracil, L-folinic acid and levamisole

**Primary outcome(s)**

Survival, recurrence, cost-effectiveness, quality of life.

**Key secondary outcome(s)**

Not provided at time of registration

**Completion date**

31/10/2003

## Eligibility

**Key inclusion criteria**

Patients who have had apparently curative surgery for Duke's A, B or C colorectal cancer within the past three months are eligible for inclusion in QUASAR.

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Not Specified

**Sex**

Not Specified

**Key exclusion criteria**

There are no definite exclusion criteria but patients must be considered fit by their clinicians to undergo six months chemotherapy.

**Date of first enrolment**

01/05/1994

**Date of final enrolment**

31/10/2003

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**  
**University of Birmingham Clinical Trials Unit**  
Birmingham  
United Kingdom  
B15 2RR

## **Sponsor information**

**Organisation**  
Medical Research Council (MRC) (UK)

## **Funder(s)**

**Funder type**  
Research council

**Funder Name**  
Medical Research Council

**Alternative Name(s)**  
Medical Research Council (United Kingdom), UK Medical Research Council, Medical Research Committee and Advisory Council, MRC

**Funding Body Type**  
Government organisation

**Funding Body Subtype**  
National government

**Location**  
United Kingdom

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	06/05/2000		Yes	No
<a href="#">Results article</a>	results	01/08/2000		Yes	No
<a href="#">Results article</a>	results	15/12/2007		Yes	No
<a href="#">Results article</a>	results	01/04/2011		Yes	No
<a href="#">Plain English results</a>				No	Yes